A brain proteomic investigation of rapamycin effects in the Tsc1+/- mouse model

Hendrik Wesseling1, Ype Elgersma2, Sabine Bahn1,2

  • 1Department of Chemical Engineering and Biotechnology, University of Cambridge, Tennis Court Road, Cambridge, CB2 1QT UK.

Molecular Autism
|August 5, 2017
PubMed
Abstract

Insights

Tuberous sclerosis complex (TSC) involves brain changes, with rapamycin treatment normalizing some molecular pathways. This research offers potential new drug targets for autism spectrum disorders and other neurodegenerative diseases.

Area of Science:

  • Neuroscience
  • Genetics
  • Biochemistry

Background:

  • Tuberous sclerosis complex (TSC) is a rare genetic disorder linked to epilepsy, intellectual disability, and autism.
  • It stems from inactivating mutations in TSC1 or TSC2 genes, leading to mTOR hyperactivation.
  • mTOR inhibitors, like rapamycin, show promise in treating TSC symptoms.

Purpose of the Study:

  • Identify molecular changes in the brain of Tsc1+/- mice associated with social and cognitive deficits.
  • Investigate the molecular effects of rapamycin treatment on these deficits.

Main Methods:

  • Proteomic analysis using LC-MS^E to detect protein level changes in the frontal cortex and hippocampus of Tsc1+/- mice and controls.
  • Validation of identified changes using selected reaction monitoring (SRM).
  • Protein Set Enrichment Analysis to identify dysregulated molecular pathways.

Main Results:

  • Proteomic analysis revealed significant protein changes in the hippocampus (108 proteins) and frontal cortex (51 proteins) of Tsc1+/- mice.
  • Key affected pathways included myelination, dendrite development, and oxidative stress, with upregulation of ribosomal proteins and mTOR kinase.
  • Rapamycin treatment significantly altered protein expression in Tsc1+/- mice, affecting pathways like oxidative stress and apoptosis, and normalizing 33 altered proteins, including those related to oxidative stress and myelin.

Conclusions:

  • Molecular alterations in Tsc1+/- mouse brains are more pronounced in the hippocampus.
  • Myelination and oxidative stress pathways are significantly affected and partially normalized by rapamycin.
  • Findings suggest potential therapeutic targets for autism spectrum disorders and other neurodegenerative diseases, warranting further investigation of mTOR inhibitors.